AST-120 for functional abnormalities of HDL in patients with CKD

AST-120 for functional abnormalities of HDL in patients with CKD - CKD-HDL and AST-120

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012838

Enrollment

Registered

2014-01-15

Start date

2014-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Treatment using AST-120 for 6 months in patients with CKD stage4 or 5. No treatment with AST-120 in patients with CKD stage4 or 5. No treatment with AST-120 in patients with normal kidney function.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age of patients is more than 20 years old. Patients with normal kidney function or CKD stage 4 or 5.

Exclusion criteria

Exclusion criteria: Age of patients is less than 20 years old. Patients during pregnancy.

Design outcomes

Primary

Measure	Time frame
HDL functions to macrophages, such as inflammatory response and lipid handling. Change of proteins or uremic toxins in HDL molecules.	—

Countries

Japan

Contacts

Public ContactSuguru Yamamoto

Niigata University Graduate School of Medical and Dental Sciences Clinical Nephroscience

yamamots@med.niigata-u.ac.jp0252270436

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026